Novel agents for diffuse large B-cell lymphoma

Abstract

Introduction: Although diffuse large B-cell lymphoma (DLBCL) is commonly considered as a cancer with a high cure rate with conventional therapies recent studies demonstrate that different biological variants of DBLCL exist, and that patients with one DLBCL variant and DLBCL patients who relapse early following rituximab-based therapy have markedly poorer outcomes with conventional management strategies. Over the last decade, there has been an increasing exploration of novel therapies derived from improved understanding of DLBCL biology and tumor–host interactions.

Areas covered: This review examines the biological basis for novel therapeutic approaches in DLBCL and the early clinical data on compounds derived from this research. A description of the expanding options of novel agents and combination therapies for patients with poor risk DLBCL is provided.

Expert opinion: Several promising novel agents and novel therapeutic combinations are under development for patients with poor risk DLBCL. Carefully designed clinical trials that build on our improved understanding of DLBCL biology and utilize tissue samples to examine the activity of novel combination therapies should expand treatment options for DLBCL patients in the future.

Keywords::

• cyclin-dependent kinase inhibitors
• diffuse large B-cell lymphoma
• immunomodulating agents
• lymphoma
• novel therapies
• proteasome inhibitors
• PKC inhibitor
• spleen tyrosine kinase inhibitor